Metabolism, Excretion, and Pharmacokinetics of Selumetinib, an MEK1/2 inhibitor, in Healthy Adult Male Subjects.

Angela W Dymond,Colin Howes,Christine Pattison,Karen So,Gabriella Mariani, Mark Savage,Stuart Mair,Gill Ford,Paul Martin

Clinical Therapeutics（2016）

引用 25|浏览4

暂无评分

摘要

The findings from this study will inform the label and will contribute to the understanding of the clinical pharmacology of selumetinib. ClinicalTrials.gov identifier: NCT01931761.

查看译文

关键词

excretion,metabolism,pharmacokinetics,selumetinib

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要